Endocrine and Neuroendocrine Cancers
Endocrine and neuroendocrine tumors originate from endocrine cells but are heterogeneous in terms of clinical presentation, disease outcome, and treatments available. This Special Issue addresses specific aspects of pre-clinical, clinical, and translational research and clinical management of these...
Saved in:
| Other Authors: | , , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_96675 | ||
| 005 | 20230202 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230202s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-5764-9 | ||
| 020 | |a 9783036557632 | ||
| 020 | |a 9783036557649 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-5764-9 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Berruti, Alfredo |4 edt | |
| 700 | 1 | |a Amoroso, Vito |4 edt | |
| 700 | 1 | |a Fazio, Nicola |4 edt | |
| 700 | 1 | |a Berruti, Alfredo |4 oth | |
| 700 | 1 | |a Amoroso, Vito |4 oth | |
| 700 | 1 | |a Fazio, Nicola |4 oth | |
| 245 | 1 | 0 | |a Endocrine and Neuroendocrine Cancers |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (198 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Endocrine and neuroendocrine tumors originate from endocrine cells but are heterogeneous in terms of clinical presentation, disease outcome, and treatments available. This Special Issue addresses specific aspects of pre-clinical, clinical, and translational research and clinical management of these diseases with the aim of providing novel insights, addressing current unmet needs, and discussing future treatment perspectives. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a neuroendocrine neoplasm | ||
| 653 | |a neuroendocrine carcinoma | ||
| 653 | |a Ki67 labeling index | ||
| 653 | |a Ki67 proliferation index | ||
| 653 | |a adrenocortical tissues | ||
| 653 | |a EMT | ||
| 653 | |a epithelial markers | ||
| 653 | |a mesenchymal markers | ||
| 653 | |a recurrence-free survival | ||
| 653 | |a neuroendocrine neoplasms | ||
| 653 | |a molecular targeted therapies | ||
| 653 | |a mTOR inhibitors | ||
| 653 | |a somatostatin analogs | ||
| 653 | |a TPH inhibitors | ||
| 653 | |a meta-analysis | ||
| 653 | |a medullary thyroid cancer | ||
| 653 | |a calcitonin | ||
| 653 | |a MEN2 | ||
| 653 | |a gene carriers | ||
| 653 | |a adrenocortical cancer | ||
| 653 | |a metastatic pheochromocytoma | ||
| 653 | |a metastatic paraganglioma | ||
| 653 | |a checkpoint inhibitors | ||
| 653 | |a avelumab | ||
| 653 | |a ipilimumab | ||
| 653 | |a nivolumab | ||
| 653 | |a pembrolizumab | ||
| 653 | |a neuroendocrine tumor | ||
| 653 | |a GEP-NET | ||
| 653 | |a PET/CT | ||
| 653 | |a PRRT | ||
| 653 | |a DOTATOC | ||
| 653 | |a crcinoid crisis | ||
| 653 | |a neuroendocrine tumors | ||
| 653 | |a hemodynamic instability | ||
| 653 | |a octreotide | ||
| 653 | |a neuroendocrine | ||
| 653 | |a molecular profiling | ||
| 653 | |a targeted therapies | ||
| 653 | |a mutation | ||
| 653 | |a fusion | ||
| 653 | |a ctDNA | ||
| 653 | |a anaplastic thyroid carcinoma | ||
| 653 | |a chemotherapy | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a tumors associated macrophages | ||
| 653 | |a radiotherapy | ||
| 653 | |a molecular targeted therapy | ||
| 653 | |a gastroenteropancreatic neuroendocrine neoplasms | ||
| 653 | |a patient-derived xenograft | ||
| 653 | |a tumor spheroids | ||
| 653 | |a somatostatin receptor-2 | ||
| 653 | |a near infrared-labelled octreotide analog | ||
| 653 | |a management | ||
| 653 | |a Delphi | ||
| 653 | |a consensus | ||
| 653 | |a pancreatic neuroendocrine tumor | ||
| 653 | |a everolimus | ||
| 653 | |a angiogenesis | ||
| 653 | |a circulating cells | ||
| 653 | |a biomarkers | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6620 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/96675 |7 0 |z DOAB: description of the publication |